Asarfi Hospital Limited

Financial Performance Highlights

FY26 Consolidated Performance:

  • Revenue from operations increased by 42% YoY to ₹173.5 crores (vs. ₹121 crores in FY25)
  • EBITDA grew by 42% to ₹35.3 crores with EBITDA margin maintained at 20%
  • EBIT increased by 44% to ₹26.4 crores
  • Profit After Tax (PAT) grew by 58% YoY to ₹16.7 crores with PAT margin improving to 10%
  • Delivered revenue CAGR of 28%, EBITDA CAGR of 34%, and PAT CAGR of 31% over last four years

Q4 FY26 Consolidated Performance:

  • Revenue of ₹45.2 crores, registering 29% YoY growth
  • EBITDA stood at ₹7.7 crores with EBITDA margin of 17%
  • PAT increased by 9% YoY to ₹3.9 crores

Operational Metrics

Hospital Capacity & Infrastructure:

  • Currently operating two hospitals with combined bed capacity of 350 beds
  • 285 beds in super specialty hospital
  • 65 beds in cancer hospital (one of only three dedicated cancer hospitals in Jharkhand)
  • Super specialty hospital offers 23+ specialized departments including Cardiology, Neuroscience, General Medicine, Orthopedic, Gastroenterology, Pediatrics, and Critical Care services

FY26 Operational Performance:

  • IPD revenue increased by 46%, OPD revenue grew by 34%
  • In-patient volume crossed 16,000 patients
  • Out-patient volume increased to approximately 1.38 lakh patients
  • Total surgeries increased by 26% YoY to over 6,300 procedures
  • ARPOB improved significantly to ₹23,000
  • Cancer hospital occupancy improved to 42%

Recent Infrastructure Enhancements:

  • Expanded cardiac care capacity from 25 beds to 45 beds
  • Strategically restructured cardiology unit to enhance operational efficiency
  • Installed GE Healthcare dual-detector SPECT gamma camera, enhancing nuclear medicine diagnostic and therapeutic capabilities
  • Operationalized advanced Philips Azurion cath lab during March 2026, strengthening interventional cardiology capabilities

Growth Strategy & Future Outlook

Vision 2028 Roadmap:

  • Target scaling overall bed capacity to 500+ beds
  • Achieve revenue of approximately ₹400 crores
  • Improve EBITDA margin to 23-25%

Key Growth Drivers:

  • Expansion of cancer hospital capacity from 65 beds to 150 beds
  • Establishment of bone marrow transplant unit and ramp-up of transplant services
  • Exploration of strategic management contracts and partnerships in nearby regions
  • Potential inorganic growth through acquisitions

FY27 Guidance:

  • Revenue target of ₹260 crores
  • PAT margin target of 13-15%
  • EBITDA margin target of at least 22%

Government Schemes & Reimbursements

Ayushman Bharat Scheme:

  • Operational in cancer hospital only
  • Contributes approximately 15% of total cancer hospital revenue
  • Government scheme reimbursements contribute 10-12% of overall revenue
  • Aging profile of receivables is around 6-7 months

Capital Expenditure Plans

Near-term Capex:

  • Cancer hospital bed expansion (65 to 150 beds): ₹2-3 crores (to be funded through internal accruals)
  • Healthcare Management Research Institute: ₹8-10 crores
  • Total FY27 capex expected to be less than ₹15 crores

Funding Position:

  • Current cash holding: ₹8-10 crores
  • No immediate debt requirements planned
  • Future major capex may require external funding depending on opportunities

Corporate Developments

Main Board Migration:

  • Company has decided to migrate to main board
  • Eligibility criteria expected to be met after July 2026
  • Process has been initiated

Potential Merger/Acquisition:

  • Technical issues being resolved for proposed merger of another hospital
  • Delay caused by inheritance issues with deceased shareholders' heirs
  • Expected to be completed in current financial year

CSR Initiatives

Community Healthcare Programs:

  • Through Asarfi Charitable Trust, deployed ₹21.3 lakhs towards HPV screening and awareness program
  • Benefited approximately 650 underprivileged women in Dhanbad
  • Focused on early detection of cervical cancer through RT-PCR and DNA testing
  • Continued healthcare awareness campaigns, health camps, and outreach initiatives across multiple districts of Jharkhand

Challenges & Constraints

Bone Marrow Transplant Unit Delay:

  • Approval delayed due to Jharkhand's organ transplant policy not being in good state
  • All arrangements completed (doctors hired, equipment ready)
  • Expected timeline: 4-5 months for approval
  • Not expected to contribute significantly to FY27 revenue

Government Scheme Challenges:

  • Administrative delays in government approvals and reimbursements
  • Political uncertainty affecting scheme stability
  • Cash realization pressures from cashless treatment schemes

Q&A Session Highlights

Expansion Strategy:

  • Company developing models for hospital management contracts
  • Planning to increase number of hospitals under management
  • Focusing on 10 neighboring districts for patient acquisition

Cancer Hospital Performance:

  • FY26 revenue: ₹33 crores (vs. ₹20 crores previous year)
  • Significant growth potential due to limited competition in region
  • Daycare procedures contributing to revenue beyond bed capacity

Margin Improvement Drivers:

  • Focus on improving case mix
  • Cost management initiatives
  • Patients from distant locations willing to pay more